Company Performance Metrics
- Miroslaw Wrobel: Co-Founder & Head of Research
Sonovum specializes in ultrasound brain monitoring. Currently, we are the only company worldwide to be able to non-invasively monitor minuscule changes in the cellular and molecular structure of brain tissue. With our newly developed technology, Acoustocerebrography (ACG), we can monitor these changes in acute settings as well as Permanent
Monitoring settings.
Sonovum is thus able to detect events previously undetected by traditional methods. Furthermore, ACG allows for a detection of these events while they occur, as it monitors brain tissue continuously. This enables us to determine indicators for pathologic conditions that so far even specialists have been unable to discover.
Clinical trials with Sonovum's Acoustocerebrographs have shown, for example, that ACG is able to identify and classify strokes as well as pre-qualify White Matter Lesions (WML).
What is more, they support the conclusion that other pathologic changes will also be visible; such as Intracranial Pressure (ICP), Dementia or Septisemia. Further hypotheses are being researched in cooperation with selected University Medical Centers.
Sonovum's founders are able to build on 20 years of research and application experience in Molecular Acoustics, CAMUD (Computer Aided Multispectral Ultrasound Diagnostics) technology and ultrasound. We are headquartered at BIOCUBE center of competence, Old Trade Fair, Leipzig.
